Archives
Gastrin I (human): Atomic Insights for Gastric Acid Secre...
Gastrin I (human): Atomic Insights for Gastric Acid Secretion Pathway Research
Executive Summary: Gastrin I (human) is an endogenous regulatory peptide (CAS 10047-33-3, MW 2098.22 Da) used to stimulate gastric acid secretion via CCK2 receptor activation, with applications in gastrointestinal physiology and pharmacokinetic research (APExBIO). It is supplied at ≥98% purity, validated by HPLC and MS, and is soluble in DMSO at concentrations ≥21 mg/mL but insoluble in water and ethanol. Recent studies confirm its utility in advanced human intestinal organoid models for investigating gastric acid secretion and drug absorption mechanisms (Saito et al., 2025). The peptide is stable when stored desiccated at -20°C, but solutions are not suitable for long-term storage. These attributes make Gastrin I (human) a cornerstone for reproducible, mechanistic studies in translational gastroenterology.
Biological Rationale
Gastrin I (human) is a peptide hormone produced by G cells in the gastric antrum. It serves as a primary stimulus for gastric acid secretion, acting through the cholecystokinin-B/gastrin (CCK2) receptor on parietal cells (APExBIO). Stimulation of these receptors triggers intracellular signaling cascades that ultimately increase activity of the H+/K+-ATPase (proton pump), leading to acid secretion into the gastric lumen. The peptide is integral to the regulation of digestive processes and plays a central role in homeostatic gastric pH control. In translational research, Gastrin I (human) is widely used to model physiological and pathophysiological conditions, including gastric hyperacidity and gastrointestinal motility disorders (Saito et al., 2025).
Mechanism of Action of Gastrin I (human)
Gastrin I (human) binds to the CCK2 receptor (also known as the gastrin receptor), which is a G protein-coupled receptor highly expressed on gastric parietal and enterochromaffin-like cells. Upon binding, the receptor activates phospholipase C, leading to the generation of inositol trisphosphate (IP3) and diacylglycerol (DAG). These second messengers increase intracellular Ca2+ concentration and activate protein kinase C (PKC), respectively (Saito et al., 2025). This cascade enhances the insertion and activity of the H+/K+-ATPase in the parietal cell membrane, resulting in increased secretion of gastric acid. Gastrin I also promotes histamine release from enterochromaffin-like (ECL) cells, which further potentiates acid secretion via H2 receptors on parietal cells.
Evidence & Benchmarks
- Gastrin I (human) exhibits ≥98% purity by HPLC and mass spectrometry under standard QC protocols (APExBIO product page).
- Induces dose-dependent gastric acid secretion in vitro in human parietal cell assays at 10–100 nM concentrations and 37°C, pH 7.4 (Saito et al., 2025, DOI).
- Activates CCK2 (gastrin) receptor signaling with measurable increases in intracellular Ca2+ within 5–15 min post-application (Saito et al., 2025, DOI).
- Stable as a dry lyophilized powder when stored desiccated at -20°C for up to 24 months (APExBIO, product page).
- Enables reliable modeling of gastric acid secretion pathways in hiPSC-derived intestinal organoids, outperforming traditional Caco-2 assays in physiological relevance (Saito et al., 2025, DOI).
For a strategic perspective on integrating Gastrin I (human) with organoid models, see Redefining Gastric Acid Secretion Pathway Research: Strat..., which offers mechanistic and translational best practices not detailed here.
Applications, Limits & Misconceptions
Gastrin I (human) is primarily applied in:
- Gastric acid secretion pathway research using in vitro parietal cell and organoid models.
- CCK2 receptor agonist studies for dissecting receptor-mediated signal transduction.
- High-definition pharmacokinetic modeling in hiPSC-derived intestinal organoids (Saito et al., 2025).
- Translational gastrointestinal disorder research, including studies on hypergastrinemia and peptic ulcer disease.
For deeper mechanistic analysis, Gastrin I (human): Advanced Insights into CCK2 Receptor A... focuses on translational receptor signaling studies, while this article emphasizes atomic, verifiable evidence and practical workflow integration.
Common Pitfalls or Misconceptions
-
Misconception: Gastrin I (human) is water-soluble.
Correction: It is insoluble in water and ethanol but soluble in DMSO at ≥21 mg/mL (APExBIO). -
Pitfall: Long-term storage of solutions is acceptable.
Correction: Solutions are not stable for long periods and should be prepared and used promptly. -
Misconception: All cell models respond equally to Gastrin I (human).
Correction: Caco-2 cells exhibit lower receptor expression and metabolic activity than hiPSC-derived organoids (Saito et al., 2025). -
Pitfall: Product purity is assumed across vendors.
Correction: Only batches validated by HPLC/MS with ≥98% purity, as offered by APExBIO, are recommended for reproducibility. -
Misconception: Gastrin I (human) directly induces all forms of gastrointestinal secretion.
Correction: Its primary effect is on gastric acid secretion via parietal cells; effects on other secretory pathways are indirect or minimal.
For a discussion of limitations in advanced in vitro models, see Gastrin I (human): Driving Innovation in Gastrointestinal..., which focuses on organoid workflow compatibility, while this article provides atomic claims and evidence boundaries.
Workflow Integration & Parameters
- Preparation: Dissolve Gastrin I (human) in DMSO to a stock concentration ≥21 mg/mL. Avoid water and ethanol as solvents (APExBIO).
- Storage: Store lyophilized solid desiccated at -20°C. Avoid repeated freeze-thaw cycles.
- Application: For in vitro assays, dilute into physiological buffer immediately before use. Typical working concentrations: 10–100 nM (validated in parietal cell and organoid models at 37°C, pH 7.4).
- Quality Control: Confirm purity (≥98%) by HPLC and MS prior to experimental use.
- Controls: Include vehicle controls (DMSO only) and, where relevant, use receptor antagonists to confirm specific CCK2 pathway activation.
The B5358 kit from APExBIO is recommended for reproducible results due to its verified purity and batch-to-batch consistency.
For a workflow-focused perspective, Gastrin I (human): Driving Innovation in High-Definition ... details integration with advanced pharmacokinetic platforms, while this article provides atomic parameterization and QC guidance.
Conclusion & Outlook
Gastrin I (human) is a rigorously validated tool for atomic-level studies of gastric acid secretion and CCK2 receptor signaling. Its high purity, defined solubility, and compatibility with hiPSC-derived organoid models position it as a reference standard for translational gastrointestinal research. As advanced in vitro models continue to evolve, Gastrin I (human) will remain essential for mechanistic dissection and therapeutic innovation in gastric physiology and drug development (Saito et al., 2025).